The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Primary analysis of HAVEN 7: emicizumab prophylaxis in infants with severe hemophilia A
Steven Pipe, MD, University of Michigan, Ann Arbor, MI, shares insights into the HAVEN 7 study (NCT04431726), which is evaluating the use of emicizumab prophylaxis in infants with severe hemophilia A without inhibitors. Due to the challenges of factor VIII prophylaxis in this population, emicizumab may demonstrate potential benefits. In this study, 55 infants were enrolled, and several efficacy endpoints were evaluated, including treated bleeds, all bleeds, treated spontaneous bleeds, and treated joint bleeds. Dr Pipe summarizes the annualized bleed rates (ABRs) observed in this study, and further comments on the safety profile of emicizumab in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Takeda, Sanofi, Regeneron/Intellia, Roche/Genentech, Pfizer, Novo Nordisk, LFB, Freeline, HEMA Biologics, GenVentiv, Equilibra Bioscience, CSL Behring, BioMarin, Bayer, ASC Therapeutics, Apcintex, Spark Therapeutics, uniQure
